5f9b4e973cf7bedc6eeed116b28df815 jcm-03-00373.pdf 3d5aeb472387b4a0081f35cbd2dc132c46e1b6b3 jcm-03-00373.pdf 8b7f9f7a68546191964bf84e88249899ec5fe77b1155c553d6b74cfb98e8e0a6 jcm-03-00373.pdf Title: The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation Subject: Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derive Keywords: direct cell reprogramming; iPSC; autologous; immune response; organ bioengineering Author: Ana Belen Alvarez Palomo 1 Creator: Microsoft® Office Word 2007 Producer: Microsoft® Office Word 2007 CreationDate: Mon Apr 7 09:36:31 2014 CEST ModDate: Mon Apr 7 09:37:57 2014 CEST Tagged: yes UserProperties: no Suspects: no Form: none JavaScript: no Pages: 15 Encrypted: no Page size: 595.32 x 841.92 pts (A4) Page rot: 0 File size: 247127 bytes Optimized: no PDF version: 1.5 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- Times New Roman,Italic TrueType WinAnsi no no no 5 0 Times New Roman TrueType WinAnsi no no no 7 0 Times New Roman,Bold TrueType WinAnsi no no no 9 0 Times New Roman,BoldItalic TrueType WinAnsi no no no 11 0 Times New Roman CID TrueType Identity-H yes no yes 13 0 ABCDEE+Cambria,Bold TrueType WinAnsi yes yes no 18 0 Times New Roman,Italic CID TrueType Identity-H yes no yes 26 0 Arial TrueType WinAnsi no no no 35 0 Jhove (Rel. 1.6, 2011-01-04) Date: 2018-06-08 04:45:57 CEST RepresentationInformation: jcm-03-00373.pdf ReportingModule: PDF-hul, Rel. 1.8 (2009-05-22) LastModified: 2018-06-07 15:04:34 CEST Size: 247127 Format: PDF Version: 1.5 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 322 FreeObjects: 251 IncrementalUpdates: 2 DocumentCatalog: PageLayout: SinglePage PageMode: UseThumbs Language: de-CH Info: Title: The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation Author: Ana Belen Alvarez Palomo 1 Subject: Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derive Keywords: direct cell reprogramming; iPSC; autologous; immune response; organ bioengineering Creator: Microsoft® Office Word 2007 Producer: Microsoft® Office Word 2007 CreationDate: Mon Apr 07 09:36:31 CEST 2014 ModDate: Mon Apr 07 09:37:57 CEST 2014 ID: 0x2cc53d2cf59b8c4a8c5b7a736be6b0e9, 0x5fdb5757fd476449a2cb8a378eac6506 Filters: FilterPipeline: FlateDecode Fonts: Type0: Font: BaseFont: TimesȀNewȀRoman,Italic Encoding: Identity-H ToUnicode: true Font: BaseFont: TimesȀNewȀRoman Encoding: Identity-H ToUnicode: true TrueType: Font: Name: F6 BaseFont: ABCDEE+Cambria,Bold FontSubset: true FirstChar: 32 LastChar: 32 FontDescriptor: FontName: ABCDEE+Cambria,Bold Flags: Nonsymbolic FontBBox: -379, -222, 1333, 778 FontFile2: true Encoding: WinAnsiEncoding Font: Name: F8 BaseFont: Arial FirstChar: 32 LastChar: 32 FontDescriptor: FontName: Arial Flags: Nonsymbolic FontBBox: -665, -210, 2000, 728 Encoding: WinAnsiEncoding Font: Name: F1 BaseFont: TimesȀNewȀRoman,Italic FirstChar: 32 LastChar: 121 FontDescriptor: FontName: TimesȀNewȀRoman,Italic Flags: Nonsymbolic FontBBox: -498, -216, 1353, 694 Encoding: WinAnsiEncoding Font: Name: F2 BaseFont: TimesȀNewȀRoman FirstChar: 32 LastChar: 242 FontDescriptor: FontName: TimesȀNewȀRoman Flags: Nonsymbolic FontBBox: -568, -216, 2000, 693 Encoding: WinAnsiEncoding Font: Name: F3 BaseFont: TimesȀNewȀRoman,Bold FirstChar: 32 LastChar: 122 FontDescriptor: FontName: TimesȀNewȀRoman,Bold Flags: Nonsymbolic FontBBox: -558, -216, 2000, 677 Encoding: WinAnsiEncoding Font: Name: F4 BaseFont: TimesȀNewȀRoman,BoldItalic FirstChar: 32 LastChar: 110 FontDescriptor: FontName: TimesȀNewȀRoman,BoldItalic Flags: Nonsymbolic FontBBox: -547, -216, 1401, 677 Encoding: WinAnsiEncoding CIDFontType2: Font: BaseFont: TimesȀNewȀRoman,Italic CIDSystemInfo: Registry: Adobe Registry: Identity Supplement: 0 FontDescriptor: FontName: TimesȀNewȀRoman,Italic Flags: Nonsymbolic FontBBox: -498, -216, 1353, 694 FontFile2: true Font: BaseFont: TimesȀNewȀRoman CIDSystemInfo: Registry: Adobe Registry: Identity Supplement: 0 FontDescriptor: FontName: TimesȀNewȀRoman Flags: Nonsymbolic FontBBox: -568, -216, 2000, 693 FontFile2: true XMP: 2014-04-07T09:36:31+02:00 Microsoft® Office Word 2007 2014-04-07T09:37:57+02:00 2014-04-07T09:37:57+02:00 Microsoft® Office Word 2007 direct cell reprogramming; iPSC; autologous; immune response; organ bioengineering False application/pdf Ana Belen Alvarez Palomo 1 Michaela Lucas 2 3 Rodney J. Dilley 4 Samuel McLenachan 5 Fred Kuanfu Chen 5 Jordi Requena 1 Marti Farrera Sal 1 Andrew Lucas 6 Inaki Alvarez 7 Dolores Jaraquemada 7 and Michael J. Edel 1 8 * The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derive direct cell reprogramming iPSC autologous immune response organ bioengineering uuid:c30fbfb5-2397-4d55-a0cf-7cca91025a82 uuid:6eb4afe1-f1da-41b5-ad37-0117c55560f8 Pages: Page: Sequence: 1 Page: Sequence: 2 Page: Sequence: 3 Page: Sequence: 4 Page: Sequence: 5 Page: Sequence: 6 Page: Sequence: 7 Page: Sequence: 8 Page: Sequence: 9 Page: Sequence: 10 Page: Sequence: 11 Page: Sequence: 12 Page: Sequence: 13 Page: Sequence: 14 Page: Sequence: 15 Checksum: 94a2cce2 Type: CRC32 Checksum: 5f9b4e973cf7bedc6eeed116b28df815 Type: MD5 Checksum: 3d5aeb472387b4a0081f35cbd2dc132c46e1b6b3 Type: SHA-1